<DOC>
	<DOCNO>NCT01538849</DOCNO>
	<brief_summary>This study investigate optimal clinical dose administration method YH4808 patient reflux esophagitis evaluate safety efficacy YH4808 oral administration .</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability Efficacy YH4808 Patients With Reflux Esophagitis</brief_title>
	<detailed_description>In result recent meta-analysis , improvement symptom first administration PPI 75 % GERD patient , symptom still sustain 50 % patient administration 3 day . Especially nocturnal secretion gastric acid effectively inhibit , 25 % GERD patient could achieve proper therapeutic effect even PPI treatment twice daily 4-8 week . YH4808 , selective K+- competitive acid blocker ( P-CAB ) , need activation gastric acid since competitively inhibit proton pump K+ . Thus , inhibition gastric acid secretion YH4808 prompt effective . In addition , inhibitive effect gastric acid secretion stimulation histamine prove powerful PPI ( esomeprazole ) sustain in-vitro/in-vivo model , 24-h inhibition gastric acid secretion especially nocturnal inhibition gastric acid secretion observe superior esomeprazole repeat dose 7 day healthy volunteer . Based nonclinical clinical outcome , exploratory phase-II clinical trial conduct determine proper treatment dose administration method YH48084 GERD patient .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1 . Subject sign write consent 2 . Male female age 20 3 . Endoscopically verified Reflux Esophagitis classify Los Angeles classification Grade A , B , C D within 2 week randomisation 1 . History presence upper gastrointestinal anatomic motor disorder 2 . Other exclusion apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>